Quotient Therapeutics
Quotient Therapeutics is a Flagship Pioneering-backed somatic genomics platform company that partners with major pharmaceutical companies to discover genetically validated drug targets using proprietary single-molecule sequencing and AI, requiring only 10–30 patients per study. Active collaborations include Merck, Pfizer, GSK, and Ipsen.
- Company typePrivate
- Founded2022
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Quotient Therapeutics does
Quotient Therapeutics is a somatic genomics platform company founded in 2022 by Flagship Pioneering, headquartered in Cambridge, MA with a genomics hub at Chesterford Research Park near Cambridge, UK. The company's core product is a proprietary platform that combines single-molecule genome sequencing — internally branded as Nanorate — with AI and computational biology to study naturally occurring genetic variation in individual cells of patient tissue. By analyzing somatic mutations that accumulate within cells over a lifetime, Quotient aims to identify disease-causal genes that traditional germline genetic approaches miss, claiming the ability to surface significant disease-driving or protecting mutations from as few as 10–30 patients per study.
The platform is delivered almost exclusively through multi-year, enterprise-scale research collaborations with major pharmaceutical companies, who pay upfront fees and milestone payments for access to Quotient's somatic genomics capabilities in specific therapeutic areas. Disclosed partnerships include a $20M upfront / up to $2.2B collaboration with Merck in inflammatory bowel disease, a cardiovascular and renal program with Pfizer, feasibility agreements with GSK in COPD, IPF, and MASH, and an extended partnership with Ipsen in ultra-rare disease. Revenue mechanics are milestone-weighted, with development, regulatory, and commercial milestones representing the largest potential value components. The customer base is a small set of large-cap pharma counterparties, and several deals flow through Flagship Pioneering's pre-existing framework agreements with Pfizer and GSK.
Quotient is led by a team that combines academic co-founders from the Wellcome Sanger Institute and UT Southwestern (including Sir Mike Stratton, Peter Campbell, and Inigo Martincorena) with experienced biotech operators such as CEO Rahul Kakkar (previously CEO of Pandion, sold to Merck for $1.85B, and founder/CMO of Corvidia, sold to Novo Nordisk for $2.1B), CDO Andrew Bayliffe (ex-GSK), and CFO Susan Keefe. The company has 11–50 employees and has not disclosed product revenue; the Flagship-originated $50M initial commitment in November 2023 remains the only disclosed funding event to date.
Quotient Therapeutics firmographics
Firmographics- Name
- Quotient Therapeutics
- Legal name
- Quotient Therapeutics, Inc.
- Website
- https://quotient-tx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Quotient Therapeutics is a Flagship Pioneering-backed somatic genomics platform company that partners with major pharmaceutical companies to discover genetically validated drug targets using proprietary single-molecule sequencing and AI, requiring only 10–30 patients per study. Active collaborations include Merck, Pfizer, GSK, and Ipsen.
- Ownership category
- akta.pro rank
Quotient Therapeutics industry classification
Industry- Product category
- Drug Target Discovery and Somatic Genomics Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Quotient Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Quotient Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research Collaboration Upfront Payments: Pharmaceutical partners pay upfront fees to access Quotient's somatic genomics platform for drug target discovery in specific disease areas. Example: $20 million upfront from Merck for IBD collaboration.
- Milestone Payments: Quotient earns development, regulatory, and commercial milestone payments as partnered programs progress. Example: up to $2.2 billion total deal value with Merck including milestones.
- Initial Funding: Flagship Pioneering made an initial commitment of $50 million to advance development of the company's platform and pursue a pipeline of medicines.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Quotient Therapeutics product offering
Product offeringCore offering
Quotient Therapeutics operates a proprietary Somatic Genomics Platform that uses single-molecule genome sequencing combined with AI and computational biology to identify somatic mutations in patient tissue that cause or protect against disease. The company translates these discoveries into genetically-validated drug targets and partners with major pharmaceutical companies on multi-year research collaborations and milestone-based development programs.
Product overview
Quotient Therapeutics operates as a platform company offering a unified Somatic Genomics Platform that integrates proprietary genome sequencing technology with AI and computational biology tools. The platform enables researchers to study naturally accumulated genetic mutations in patient tissue to identify disease-causal drug targets across multiple therapeutic areas including autoimmune, cardiometabolic, oncology, and rare diseases. The company's core technology is the Somatic Genomics Platform, which serves as the foundation for both internal drug discovery programs and external partnerships with pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Somatic Genomics Platform Proprietary platform that uses single molecule genome sequencing and AI-driven computational biology to identify somatic mutations in patient tissue that cause or protect against disease, enabling discovery of genetically-validated drug targets for pharmaceutical partners.
- Industrialized Somatic Genomics Technology
Quantifiable outcome
- Requires only 10-30 patients per study to find significant disease-driving mutations
- +1 more outcomes
Companies that use Quotient Therapeutics
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Quotient Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Quotient Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Merck (MSD)coreMulti-year research collaboration to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient's somatic genomics platform. Quotient receives $20 million upfront and up to $2.2 billion in development, regulatory, and commercial milestones. The partnership leverages Quotient's platform to analyze patient tissue for somatic mutations that cause or protect from disease.
- IpsenminorExtended partnership focused on ultra-rare disease therapy development using Quotient's somatic genomics approach.
- GSKcoreFeasibility agreements under the Flagship-GSK framework collaboration to discover and validate novel treatments for COPD, idiopathic pulmonary fibrosis (IPF), and metabolic dysfunction-associated steatohepatitis (MASH). If GSK elects to progress, programs advance through preclinical activities with exclusive option for clinical studies.
- PfizercoreResearch collaboration under Flagship's strategic partnership with Pfizer to discover new targets for cardiovascular and renal diseases. Quotient and Pioneering Medicines jointly conduct research analyzing somatic mutations in diseased patient tissue to inform development of transformative therapies.
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
Quotient Therapeutics competitors and assessment
Company assessmentDirect peers
- Generate Biomedicines: Flagship Pioneering sister company combining generative AI with biology to design novel protein therapeutics. Comparable as a Flagship-originated platform biotech that pairs proprietary computational technology with multi-target pharma partnerships across multiple therapeutic areas.
- Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology to identify novel targets. Comparable as a platform company monetizing proprietary data and AI capabilities through pharma partnerships and internal pipeline programs.
- Maze Therapeutics: Genetics-driven drug discovery company using functional genomics and variant interpretation to identify causal targets. Comparable as a platform translating human genetic variation into validated drug targets through pharma partnerships and an internal pipeline.
- Recursion Pharmaceuticals: AI-enabled drug discovery platform using high-throughput biology, imaging, and machine learning to identify targets and advance small molecules. Comparable as a publicly-listed platform company monetizing proprietary data and AI through partnerships and internal programs.
- Isomorphic Labs: Alphabet/DeepMind spin-off applying AlphaFold-derived AI to drug discovery and target identification. Comparable as an AI-first platform pursuing both partnered programs and internal pipeline assets across multiple therapeutic areas.
- Xaira Therapeutics: AI-native drug discovery company founded in 2023 with significant capital, applying foundation models to biology and target ID. Comparable as a recent, well-capitalized entrant into AI-enabled target discovery pursuing pharma partnerships and internal development.
- Tessera Therapeutics: Flagship Pioneering company developing gene writing technology with both internal programs and pharma partnerships. Comparable as a Flagship-originated platform company pairing novel molecular technology with multi-billion-dollar pharma collaborations.
- Atomwise: AI-driven small molecule discovery company using structure-based design and partnerships with pharma. Comparable as an AI-first platform company commercializing target and molecule discovery through enterprise collaborations with major pharma.
Broad incumbents
- Schrödinger: Established computational chemistry and predictive modeling platform with both software and internal drug discovery programs. Comparable as a broader computational drug discovery incumbent with mature pharma relationships, but less focused on omics-driven target identification.
Emerging players
- Owkin: AI-biomedicine company combining multimodal patient data, including genomics, with machine learning to discover targets and develop diagnostics. Comparable as an emerging player applying AI to omics-driven target identification, with a stronger diagnostics orientation than Quotient.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Quotient Therapeutics social profiles
Digital presenceQuotient Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quotient Therapeutics leadership team
Management profileNumber of profiles
Profiles13 records
Quotient Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quotient Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quotient Therapeutics
What does Quotient Therapeutics do?
Quotient Therapeutics operates a proprietary Somatic Genomics Platform that uses single-molecule genome sequencing combined with AI and computational biology to identify somatic mutations in patient tissue that cause or protect against disease. The company translates these discoveries into genetically-validated drug targets and partners with major pharmaceutical companies on multi-year research collaborations and milestone-based development programs.
Is Quotient Therapeutics a public or private company?
Quotient Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Quotient Therapeutics founded?
Quotient Therapeutics was founded in 2022. It employs 51 to 100 people.
Where is Quotient Therapeutics based?
Quotient Therapeutics is headquartered in London, United Kingdom, in the Europe region.
How does Quotient Therapeutics make money?
Three revenue lines are on record. Research Collaboration Upfront Payments are the primary driver. The others are milestone Payments and initial Funding.
Who are Quotient Therapeutics's main competitors?
Direct peers on record are Generate Biomedicines, Insitro, Maze Therapeutics, Recursion Pharmaceuticals, Isomorphic Labs, Xaira Therapeutics, Tessera Therapeutics and Atomwise. Schrödinger is listed as a broad incumbent. Owkin is listed as an emerging player.
Does Quotient Therapeutics have an API?
No public API is recorded for Quotient Therapeutics.
What industry is Quotient Therapeutics in?
Quotient Therapeutics's product category is Drug Target Discovery and Somatic Genomics Biotechnology. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.